Sennoside B抑制三阴性乳腺癌细胞的恶性表型，抑制ERK/AKT/STAT5信号通路

IF 2.9 4区医学 Q2 PATHOLOGY

Pathology, research and practice Pub Date : 2025-02-13 DOI:10.1016/j.prp.2025.155842

Li-jun Li, Shan-shan Xie

{"title":"Sennoside B抑制三阴性乳腺癌细胞的恶性表型，抑制ERK/AKT/STAT5信号通路","authors":"Li-jun Li, Shan-shan Xie","doi":"10.1016/j.prp.2025.155842","DOIUrl":null,"url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. Treatment alternatives for TNBC are very limited and new therapeutic drugs are needed. Sennoside B (SB) is a dianthrone glycoside that has shown antitumor activity in osteosarcoma. However, the role of SB in TNBC remains unclear. This study aims to investigate the role and potential mechanism of SB in TNBC. MTT, colony formation, scratch, and Transwell assays were conducted to examine the malignant behaviors of TNBC cells under different doses of SB treatment. RT-qPCR and western blotting were utilized to detect mRNA or protein levels of molecules. The results revealed that SB treatment dose-dependently restrained TNBC cell proliferation, migration, invasiveness as well as epithelial-mesenchymal transition. Mechanistically, SB suppressed extracellular signal-regulated kinase (ERK), Ak strain transforming protein (AKT), and signal transducer and activator of transcription 5 (STAT5) phosphorylation in TNBC cells. In conclusion, SB treatment impairs the cell aggressiveness of TNBC and blocks ERK/AKT/STAT5 signaling in TNBC cells.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"269 ","pages":"Article 155842"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sennoside B inhibits malignant phenotypes of triple-negative breast cancer cells and represses ERK/AKT/STAT5 signaling\",\"authors\":\"Li-jun Li, Shan-shan Xie\",\"doi\":\"10.1016/j.prp.2025.155842\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. Treatment alternatives for TNBC are very limited and new therapeutic drugs are needed. Sennoside B (SB) is a dianthrone glycoside that has shown antitumor activity in osteosarcoma. However, the role of SB in TNBC remains unclear. This study aims to investigate the role and potential mechanism of SB in TNBC. MTT, colony formation, scratch, and Transwell assays were conducted to examine the malignant behaviors of TNBC cells under different doses of SB treatment. RT-qPCR and western blotting were utilized to detect mRNA or protein levels of molecules. The results revealed that SB treatment dose-dependently restrained TNBC cell proliferation, migration, invasiveness as well as epithelial-mesenchymal transition. Mechanistically, SB suppressed extracellular signal-regulated kinase (ERK), Ak strain transforming protein (AKT), and signal transducer and activator of transcription 5 (STAT5) phosphorylation in TNBC cells. In conclusion, SB treatment impairs the cell aggressiveness of TNBC and blocks ERK/AKT/STAT5 signaling in TNBC cells.</div></div>\",\"PeriodicalId\":19916,\"journal\":{\"name\":\"Pathology, research and practice\",\"volume\":\"269 \",\"pages\":\"Article 155842\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology, research and practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0344033825000342\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033825000342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

三阴性乳腺癌（TNBC）是最致命的乳腺癌亚型。TNBC的治疗选择非常有限，需要新的治疗药物。番泻皂苷B （Sennoside B， SB）是一种对骨肉瘤具有抗肿瘤活性的dianthrone糖苷。然而，SB在TNBC中的作用尚不清楚。本研究旨在探讨SB在TNBC中的作用及其潜在机制。采用MTT法、菌落形成法、划痕法和Transwell法检测不同剂量SB处理下TNBC细胞的恶性行为。RT-qPCR和western blotting检测分子mRNA或蛋白水平。结果显示，SB治疗剂量依赖性地抑制TNBC细胞的增殖、迁移、侵袭性以及上皮-间质转化。在机制上，SB抑制TNBC细胞外信号调节激酶（ERK）、Ak菌株转化蛋白（AKT）和信号传导和转录激活因子5 （STAT5）磷酸化。综上所述，SB治疗会损害TNBC细胞的侵袭性，阻断TNBC细胞中的ERK/AKT/STAT5信号通路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sennoside B inhibits malignant phenotypes of triple-negative breast cancer cells and represses ERK/AKT/STAT5 signaling

Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. Treatment alternatives for TNBC are very limited and new therapeutic drugs are needed. Sennoside B (SB) is a dianthrone glycoside that has shown antitumor activity in osteosarcoma. However, the role of SB in TNBC remains unclear. This study aims to investigate the role and potential mechanism of SB in TNBC. MTT, colony formation, scratch, and Transwell assays were conducted to examine the malignant behaviors of TNBC cells under different doses of SB treatment. RT-qPCR and western blotting were utilized to detect mRNA or protein levels of molecules. The results revealed that SB treatment dose-dependently restrained TNBC cell proliferation, migration, invasiveness as well as epithelial-mesenchymal transition. Mechanistically, SB suppressed extracellular signal-regulated kinase (ERK), Ak strain transforming protein (AKT), and signal transducer and activator of transcription 5 (STAT5) phosphorylation in TNBC cells. In conclusion, SB treatment impairs the cell aggressiveness of TNBC and blocks ERK/AKT/STAT5 signaling in TNBC cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.